Oral medicines plus carfilzomib for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests how well an oral treatment plan (cyclophosphamide and dexamethasone) combined with carfilzomib works in people whose multiple myeloma has come back or not responded. It may help shrink the myeloma and control symptoms after treatment with medicines like lenalidomide.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older.
- Your multiple myeloma has come back or is resistant to treatment, and it can be measured by blood or urine tests.
- You have had at least one prior treatment, and it included lenalidomide or you were treated with lenalidomide alone.
- Your body is strong enough for study treatment (performance status 0 to 2).
- Your blood counts and organs are in a safe range (enough white blood cells and platelets, kidney function acceptable, and liver numbers not too high).
- You can swallow and take oral medicines, and any side effects from past treatment are mostly gone or stable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (mezigdomide, carfilzomib, and dexamethasone) for people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see if this new drug mix can help control the cancer again.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in patients whose multiple myeloma has come back or stopped responding to prior treatment. The goal is to see if this combination can shrink the cancer and help patients whose disease has high-risk features, like certain chromosome changes.
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
This Phase 2 trial tests iberdomide plus daratumumab, carfilzomib, and dexamethasone in people whose multiple myeloma has come back or not responded. The goal is to increase how often patients reach “MRD-negative” status, meaning very small amounts of cancer cells are not detectable, which may help improve outcomes.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.